Recent research, however, suggests that the beneficial effects of GLP-1R agonists on NAFLD may be mediated by direct activation of the GLP-1R on hepatocytes, independent of weight loss [38,39]. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.